Chapter 108: Anticancer Drugs II: Hormonal Agents, Targeted Drugs, and Other Noncytotoxic Anticancer Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about cancer treatment,

the first image that comes to mind is this just devastating scorched earth strategy.

Right, like traditional chemotherapy.

Exactly.

You picture dropping this pharmacological bomb and it wipes out the rapidly dividing cancer cells, but you know, the collateral damage is massive.

It takes out the hair follicles, the bone marrow, the GI tract lining.

It's a blunt instrument.

I mean, those traditional cytotoxic agents like the ones you'd see in Chapter 107 of Lane's Pharmacology, they directly kill cells and they're heavily dependent on specific phases of the cell cycle.

They don't really care what the cell's long -term job is.

If it's dividing, it's a target.

But today we're diving into Chapter 108 of Lane's to figure out how modern medicine is, well, replacing those scorched earth chemo bombs with pharmacological snipers.

We're doing a deep dive into targeted anti -cancer drugs, hormonal therapies, and amino stimulants.

Which is such a fascinating shift.

It really is.

And if you're a nursing student listening to this on your commute, gearing up for your exam, our mission today is to translate this really dense pharmacology into the practical bedside implications you actually need to know.

And that distinction between cytotoxic and targeted is really the key to this whole deep dive.

These drugs lack cell cycle phase specificity.

They generally spare normal healthy cells.

But we should probably clear up a misconception right away, right?

Because targeted does not mean harmless.

Oh, absolutely not.

No.

You are essentially just trading one set of severe toxicities for another.

In fact, right at the beginning of the text, there is a massive safety alert.

Most of these drugs are recognized by NIOSH as hazardous.

Which means as a nurse, you don't get to just relax your handling protocols because the drug isn't a traditional chemo agent.

Right.

You are still wearing your hazardous drug PPE.

Exactly.

You have to protect yourself because these agents are incredibly potent.

And to see just how potent, let's start by looking at breast cancer.

The strategy here relies on manipulating the very hormones that feed the tumors.

And there is a golden rule for these hormonal drugs.

The tumor must be estrogen receptor positive or ER positive.

Okay, so it has to rely on estrogen.

Right.

Think of the estrogen receptor as like the ignition switch for the cancer cell.

If the tumor doesn't rely on estrogen to grow, if it doesn't have that switch, these drugs are completely useless.

You really have to know the genetic profile of the tumor.

So if the tumor is ER positive, the gold standard treatment is an anti -estrogen called tamoxifen.

Yes, the classic prototype.

I always picture tamoxifen as this highly selective bouncer at a nightclub.

At the breast tissue, tamoxifen stands at the door of the estrogen receptor, crosses its arms, and absolutely blocks estrogen from getting inside.

So the tumor starves.

It's a great analogy.

But tamoxifen has this bizarre double life.

Because in the uterus and the bone, it acts like a VIP host, ushering estrogen in and actually activating those receptors.

And that dual action right there is the defining characteristic of a CIRM, a Selective Estrogen Receptor Modulator.

It explains literally both the therapeutic benefits and the dangerous adverse effects.

Because it's acting differently in different tissues.

Exactly.

By activating receptors in the bone, tamoxifen actually increases bone density.

That's a fantastic secondary benefit.

But by activating receptors in the uterus, it creates a severe risk for endometrial cancer.

Wow.

Yeah.

And it also heavily increases the risk for thromboembolism.

So we're talking dangerous blood clots, DVTs, and pulmonary embolisms.

So the patient is dealing with those really serious underlying risks.

But on a day -to -day basis, they're also just miserable with hot flashes and fluid retention.

Oh, the hot flashes are notorious.

Right.

And this creates a really dangerous trap for the bedside nurse.

Say your patient complains of debilitating hot flashes,

and a provider prescribes an SSRI antidepressant, something like fluoxetine or peroxetine, to help manage them.

Why is that a textbook medication error?

It all comes down to pharmacokinetics.

See, tamoxifen is what we call a pro -dread.

Wait, so the pill itself doesn't actually do anything.

Right.

When the patient swallows the pill, it is completely inactive.

It only starts fighting cancer after it passes through the liver and gets metabolized by an enzyme called

Here's the trap.

Those specific SSRIs, fluoxetine and peroxetine, are strong inhibitors of CYP2D6.

Oh, I see where this is going.

Yeah.

If you give them together, the antidepressant basically shuts down the liver enzyme, so the tamoxifen never gets activated, and the patient's risk of a cancer recurrence just skyrockets.

That is terrifying.

So as the nurse, you have to catch that interaction.

You need to advocate for an alternative antidepressant, like maybe acetalipram or venlafaxine, which won't block that crucial liver enzyme.

Exactly.

Now, if tamoxifen is the gold standard, why do I see some patients taking a drug called anastrazole instead?

And why does the literature specify it's only for postmenopausal women?

Well, to understand anastrazole, we have to look at where estrogen actually comes from.

In premenopausal women, the ovaries are basically factories pumping out massive amounts of estrogen, Anastrazole cannot overpower the ovaries.

It just can't.

So it's totally useless for those patients.

But in postmenopausal women, the ovaries have shut down.

So where are they getting estrogen?

Their only source of estrogen comes from a peripheral process where adrenal androgens are converted into estrogen by an enzyme called aromatase.

Ah, okay.

So anastrazole is an aromatase inhibitor.

It goes after that specific conversion enzyme.

Precisely.

It cuts the supply line entirely.

It eliminates that peripheral estrogen, completely starving the ER -positive tumor.

And for postmenopausal women, it's actually more effective than tamoxifen.

And it probably avoids some of those serum side effects, right?

Yeah, it completely avoids the risks of endometrial cancer and blood clots because it isn't activating estrogen anywhere.

But the trade -off sounds brutal.

Because you are utterly depleting every single drop of other estrogen.

The text notes these patients suffer from severe musculoskeletal pain.

They'll tell you, like, every bone in my body hurts.

That's very tough on them.

And without estrogen protecting their bones, they are at a huge risk for osteoporosis.

Which is a major, major concern, especially because breast cancer itself loves to metastasize to the bone.

Oh, right.

That creates a whole new category of complications called skeletal -related events, or SREs.

We're hypercalcemia as the bone breaks down and pathologic fractures.

And to manage those SREs, we bring in drugs that inhibit osteoclasts, right?

The cells that are responsible for breaking down bone tissue.

Correct.

The text highlights two of them.

Denosumab, which is given as a sub -Q injection,

and Xeladrinate and 5e's phosphonate.

And when you administer these, you are monitoring for very specific adverse effects.

With Xeladrinate, you have to watch kidney function really carefully due to the risk of renal damage.

With Denosumab, the big concern is hypercalcemia.

But both of these drugs carry a uniquely terrifying risk that you absolutely must include in your patient education.

Which is?

Osteonecrosis of the jaw.

Wait, really?

Yes.

The bone tissue in the jaw can literally die and become exposed.

That is horrifying.

Okay, let's step back to the cancer itself.

We've talked about starving ER -positive tumors.

But what if the breast cancer isn't driven by hormones?

What if it's driven by a genetic protein like AGR2?

Then we shift our strategy.

If the tumor has an over -expression of the human epidermal growth factor receptor 2, that's AGR2, we use a targeted monoclonal antibody called Trastuzumab.

Okay, so it binds directly to the AGR2 receptor to stop cell proliferation.

Right.

But Trastuzumab carries some major black box warnings.

The first is severe cardio -toxicity.

It can cause ventricular dysfunction and profound heart failure, particularly if the patient has a history of receiving doxorubicin.

Which is that traditional chemo agent we talked about earlier.

Exactly.

And the second warning is severe hypersensitivity and infusion reactions.

So if you are a nurse hanging that first bag of Trastuzumab and your patient suddenly develops bronchospasm, wheezing or hypoxia, you don't just slow the IV rate down.

No, absolutely not.

You stop the infusion immediately.

And the text also mentions oral options for different genetic profiles, like Pelviciclub and Ribociclub.

Yeah, those are CDK46 inhibitors used alongside hormonal therapies for ER -positive cancers.

But if a patient is on Ribociclub, your nursing priority really shifts to cardiac and hepatic monitoring.

Why is that?

Because it carries a significant risk of QT prolongation and hepatotoxicity.

Okay, got it.

So we've seen how taking away estrogen starves breast tissue tumors.

Does the exact same logic apply to other hormone -driven cancers?

Like, if we look at prostate cancer, which feeds on testosterone, the strategy must be pretty similar, right?

It is the exact same logic.

The therapeutic goal is androgen deprivation therapy, or ADT.

We just want to remove the testosterone that the prostate cancer uses as fuel.

And the mainstay drug for this is Luperlide, right?

The GnRH agonist.

It essentially creates a state of chemical castration.

That's right.

I always use the analogy of car alarm to explain Luperlide to patients.

If a car alarm blurs constantly outside your window, eventually your brain just tunes it out.

Luperlide mimics GnRH.

So when it's first administered, it actually overstimulates the pituitary gland.

It forces the body to produce a massive surge of testosterone.

And clinically, that is a highly dangerous window.

Because you've just flooded the body with testosterone, so the prostate cancer gets a sudden burst of fuel.

Exactly.

We call this a tumor flare.

For the first few weeks, the patient's symptoms actually get remarkably worse.

They have increased bone pain, severe urinary obstruction.

Wait, if Luperlide causes a massive surge in testosterone at first, aren't we just pouring gasoline on the fire?

Like, how do we prevent that tumor flare from harming the patient?

We co -administer an oral androgen receptor blocker called Flutamide.

Oh, okay.

Yeah, Flutamide sits on the prostate cancer's receptors and shields them.

It blocks that initial testosterone surge from feeding the tumor.

It also mops up the roughly 10 % of androgens that are produced by the adrenal glands.

But Flutamide is highly toxic to the liver, isn't it?

Very.

As the nurse, you are drawing frequent liver function tests, AST and ALT, because it carries a risk of fatal hepatotoxicity.

So once that initial Luperlide surge is over, the car alarm effect finally kicks in.

The pituitary gland gets exhausted from the constant stimulation, the receptors downregulate, and testosterone production basically plummets to zero.

Right.

That's the therapeutic goal.

But you mentioned another option before, Degerlix.

How is that different?

Well, Degerlix is a GnRH antagonist.

Instead of overstimulating the receptors to cause fatigue, it just directly blocks them from day one.

Oh, so there is no initial testosterone surge.

Exactly.

No surge and therefore no tumor flare.

The downsides, though, are that it can cause severe injection site reactions and, just like Flutamide, requires really careful liver monitoring.

Even with these drugs, the body can be stubborn, right?

It tries to synthesize androgens elsewhere.

It does try.

And that's where abiraterone comes in.

It's a CYP17 inhibitor, meaning it blocks the enzyme needed to make androgens at literally every possible source, the testes, the adrenals, and even the tumor itself.

But blocking CYP17 doesn't just stop testosterone.

It sets off this wild chain reaction in the adrenal glands.

Yes.

This is where understanding the physiology is just critical.

The adrenal gland makes different types of hormones on basically an assembly line.

When abiraterone blocks CYP17, it shuts down the production of cortisol and sex hormones.

So what happens to all the raw materials?

The adrenal gland takes all of it and shuts it down the only open pathway, producing a massive excess of mineralocorticoids like aldosterone.

Which perfectly explains the bizarre side effects,

because mineralocorticoids force the body to hold onto sodium and water and dump potassium.

Right.

So the patient ends up with severe hypokalemia, edema, and dangerous hypertension.

All while simultaneously separating from glucocorticoid insufficiency, because they aren't making any cortisol.

And that underlying mechanism drives the primary nursing implication here.

Abiraterone must always be given with prednisone.

Because you have to replace a missing cortisol.

Exactly.

The prednisone replaces the missing cortisol, which then signals the brain to stop driving that runaway mineralocorticoid production.

You're unofficially balancing the scales.

That is fascinating.

Now the last prostate cancer treatment the text covers sounds straight out of science fiction.

Cipulisal T.

Oh, this one is incredible.

It's patient -specific immunotherapy.

They connect the patient to a machine and perform leukophoresis, right?

Pulling out the patient's own macrophages.

Then in a lab, they expose those immune cells to a specific protein called PPG -DE -SHI -SF.

Right.

They are essentially teaching the patient's own immune system what prostate cancer looks like.

And then they infuse those trained cells back into the patient.

It's a staggering feat of bioengineering.

But, you know, you have to balance the science with the clinical reality.

It's astronomically expensive.

It only provides a moderate survival benefit.

And surprisingly, it rarely even shrinks the actual tumor.

Really?

All that for just a moderate benefit?

Yeah.

Furthermore, because you are infusing activated immune cells, severe acute infusion reactions happen in over 70 % of patients.

You absolutely must pre -medicate them with acetaminophen and an antihistamine like diamond hydramine before the infusion even begins.

Okay.

Let's shift gears from those complex cellular processes to what the text calls the smart bombs of oncology.

Targeted anti -cancer drugs.

Right.

Moving away from manipulating hormones.

Exactly.

To targeting the specific enzymes and pathways cancer cells use to replicate.

We'll start with kinase inhibitors.

Kinases are basically the internal on -switches for cellular growth.

And our first prototype is Citeximab, an EGFR -tyrosine kinase inhibitor used for colorectal and head and neck cancers.

And EGFR stands for Epidermal Growth Factor Receptor, right?

Yes.

When Citeximab blocks this receptor, it stops the cancer from growing.

But because it targets epidermal receptors, your primary nursing focus is on the skin.

Right.

The text really emphasizes a severe acne -like rash on the face and upper torso.

So if Citeximab blocks epidermal growth factors, it essentially wrecks the healthy skin cells' ability to maintain themselves too.

Exactly.

And this isn't just a cosmetic issue.

The rash causes significant breakdown of the skin barrier, leading to a high risk of life -threatening staph sepsis.

And sunlight dramatically exacerbates the damage, so strict patient education regarding sun protection is totally non -negotiable.

You also have to monitor for severe hypomagnesemia and be ready for a rapid -onset airway obstruction during the first infusion.

Okay.

So Citeximab targets the skin receptors.

Imatinib is the sniper rifle for a very specific genetic anomaly, right?

It's a BCRABL inhibitor, considered the gold standard for chronic myeloid leukemia, or CML.

Yes.

CML is driven by the Philadelphia chromosome, which creates an abnormal enzyme called BCRABL that causes white blood cells to multiply out of control.

Imatinib flawlessly targets and inhibits that exact abnormal enzyme.

It's just so precise.

It's incredibly effective, but it brings issues of fluid retention, severe nausea, and it is highly terogenic, requiring strict contraceptive counseling.

The text also highlights a few other specific inhibitors, like sorifinib, which blocks multiple kinases for renal and liver cancer, but it causes terrible hand and foot syndrome and

Cretatinib is an ALK inhibitor for lung cancer, but you have to monitor lung function because it carries a risk of fatal pneumonitis.

And then there's vimorfinib for melanoma, which requires the patient to test positive for a specific genetic mutation, the BRAFV600E

mutation.

Right.

And if the patient doesn't have that exact BRAF mutation, vimorfinib does absolutely nothing.

Okay.

But the side effect profile is a total paradox.

By manipulating these highly specific genetic pathways, vimorfinib can actually cause a completely different type of cancer.

Wait, really?

Yeah.

Nearly a quarter of patients develop cutaneous squamous cell carcinoma.

So you are literally trading one cancer for another.

It really highlights how delicate these mechanisms are.

Let's move to the targeted antibodies.

Rituximab binds to the CD20 antigen found on B lymphocytes, triggering the immune system to launch a massive attack against B cell lymphoma.

Right.

But I have a logistical question here.

If Rituximab is highly effective and destroys a massive amount of tumor cells all at once, what happens to all that cellular debris?

I mean, it doesn't just vanish.

That is one of the most critical oncology emergencies a nurse will ever manage.

When those cells burst open simultaneously, they dump all their intracellular contents straight into the bloodstream.

This causes tumor lysis syndrome or TLS.

I always picture TLS like a massive demolition company collapsing an entire skyscraper all at once.

The debris instantly clogs the city streets and completely overwhelms the garbage trucks, which in this case are the kidneys.

That's a perfect analogy.

The debris consists of massive spikes in potassium, uric acid, and phosphate.

The uric acid crystallizes and causes acute renal failure, while the hyperclamia triggers fatal cardiac dysrhythmias.

So you have to be hypervigilant.

Oh, yeah.

You have to monitor for TLS heavily in the first 12 to 24 hours.

Additionally, you must screen patients for hepatitis B before starting rituximab because it can cause fatal viral reactivation.

Wow.

Okay.

Next is an antibody drug conjugate called brenteximabidotin.

I call this the Trojan horse drug.

Oh, that's a good name for it.

The antibody portion acts as the guidance system, seeking out the CD30 antigen on the cancer cell.

It binds, the cancer cell essentially swallows it up, it internalizes it, and once inside, the drug releases a highly toxic chemical payload called MMAE that stops the cell from dividing.

It's brilliant.

It is, but that payload causes collateral damage, specifically peripheral neuropathy and neutropenia.

Another really fascinating mechanism is bevacizumab.

It's an angiogenesis inhibitor.

Instead of attacking the tumor directly, it binds to VEGF.

VEGF is like the chemical distress flare that tumors shoot into the body, demanding the new blood vessels to feed it.

Right.

Bevacizumab basically intercepts that flare.

It prevents new blood vessels from forming, starving the solid tumor of its blood supply.

But because its entire mechanism revolves around disrupting blood vessel formation, every major side effect is vascular.

So it prevents the body from healing micro tears, which leads to GI perforations.

It causes severe hemorrhage, like massive hemoptysis, and completely halts wound healing.

The hard and fast nursing rule here is surgical timing.

You must stop bevacizumab at least 28 days before any elective surgery and you cannot restart it until at least 28 days after.

You simply will not heal.

It's so critical to remember that.

Finally, in the targeted section, we have bortezomib for multiple myeloma.

This is a proteasome inhibitor.

Think of the proteasome as the cellular garbage disposal.

It chops up unwanted proteins.

Okay, so what does bortezomib do?

Bortezomib jams the garbage disposal.

The cancer cell just fills up with its own toxic protein waste until it undergoes apoptosis and dies.

The main adverse effects to monitor here are peripheral neuropathy and severe weakness.

That brings us to our final group, the immunostimulants.

For this class of drugs, we've flipped the script completely.

We aren't directly poisoning the tumor or blocking its receptors.

We are hyperstimulating the patient's own immune system to do the fighting.

Exactly.

First is Zenerferon -Alpha -2B.

It enhances host immunity.

When you artificially ramp up the immune system, you predictably cause a severe flu -like syndrome, right?

Mm.

Fevers, chills, myalgia.

You do.

And you can manage those physical symptoms with acetaminophen, but there is a hidden danger.

The systemic inflammation crosses into the central nervous system, causing profound neuropsychiatric effects.

Like what?

You must continuously assess the patient for severe depression and suicidal ideation.

Wow, that's a serious side effect.

Next is Aldislucan or Interlucan -2.

Now, this immunostimulant triggers a systemic inflammatory response so profound that it generally must be administered in a hospital setting with an intensive care unit and a cardiopulmonary specialist immediately available.

And that's because of capillary leak syndrome, right?

Yes.

Normally, your blood vessels are like solid garden hoses, but the massive immune response caused by Aldislucan breaks down that vascular tone.

The garden hoses basically turn into soaker hoses.

Oh, yeah, I see.

Plasma proteins and fluid weep out of the capillaries and into the surrounding tissue.

So the blood volume drops drastically.

You get fatal hypotension.

And because there isn't enough pressure to push blood around, the organs simply stop working.

Heart failure, renal failure, GI bleeding.

It requires meticulous hemodynamic monitoring.

It's very in -depth.

Lastly, we have the bacillus calmitgarin or BCG vaccine used for bladder cancer.

It's administered intravesically, meaning it is instilled directly into the bladder through a catheter.

It provokes a localized inflammatory response that destroys the tumors lining the bladder wall.

But the clinical consideration here is wild to me.

BCG isn't just a chemical drug.

It is a live attenuated strain of tuberculosis bacteria.

Which means your infection control protocols must be totally flawless.

You are handling live mycobacterium.

You must use strict aseptic technique, dispose of all equipment and specific infectious waste bags, and educate the patient on a very unique bathroom protocol.

The bleach rule.

Yes.

Every time they void for six hours after the treatment, they must pour an equal amount of five percent bleach into the toilet and let it sit for 15 minutes before flushing to kill the bacteria.

Bleach in the toilet really puts the hazardous label into perspective.

Well, we have successfully traversed the dense pharmacology of Chapter 108.

We've taken the complex mechanisms of action from hormone blocking bouncers and tumor flare cascades to genetic snipers and Trojan horse antibodies and translated them into the cause and effect nerfing implications you actually need for your exam.

And before we go, I want to leave you with a final thought to mull over.

As we advance further into this era of precision medicine, like bioengineering a drug exclusively from a patient's own macrophages or refusing a melanoma treatment unless a specific BRAF mutation is present, we are rapidly abandoning one size fits all medicine.

It's very true.

And that means we're moving toward genetically unique side effects.

How will the day -to -day intuition of the bedside nurse evolve when you have to anticipate adverse effects that are as individualized as the patient's own DNA?

It's a profound shift in how we approach patient safety.

The treatments are getting

unimaginably precise, which means our bedside assessments have to be sharper than ever.

From all of us here at The Deep Dive in our Last Minute Lecture Study Series,

thank you for trusting us with your prep.

You've got this.

Good luck on the exam.